COMT inhibition with entacapone in the treatment of Parkinson's disease.
Rinne
U K
UK
Department of Neurology, University of Turku, Finland.
Gordin
A
A
Teräväinen
H T
HT
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000009:adverse effects / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; C071192:entacapone